{"schema_version":"secwatch.filing_event.v1","accession":"0001503274-24-000014","form_type":"8-K","ticker":"QTRX","cik":"0001503274","company_name":"Quanterix Corp","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.614629+00:00","generated_at":"2026-05-30T01:48:57.280151+00:00","sec_items":["2.02","4.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Quanterix restates prior financials for inventory errors; Q3 revenue $35.7M (+13% YoY)","bullets":["Revenue $35.7M (+13% YoY); GAAP gross margin 58.9%; reaffirms FY2024 revenue guidance $134-138M.","Restating financials for 2021-2024 due to inventory capitalization errors; non-reliance on prior statements.","Estimated restatement impacts: 2023 gross profit +$2.1M, operating loss -$2.3M; no material impact on cash or revenue.","Material weaknesses in internal control over inventory valuation continue; remediation ongoing.","Launched LucentAD Complete multi-marker Alzheimer's test; Mt. Sinai deploying blood-based biomarkers using Quanterix assays."],"urls":{"canonical":"https://secwatch.observer/filing/0001503274-24-000014","json":"https://secwatch.observer/filing/0001503274-24-000014.json","markdown":"https://secwatch.observer/filing/0001503274-24-000014.md","text":"https://secwatch.observer/filing/0001503274-24-000014.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1503274/000150327424000014/0001503274-24-000014-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1503274/000150327424000014/qtrx-20241111.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:48:57.280151+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1ea9074078ed42911a0b8ff3411399f34cbc82b6","claim":"Quanterix Corp reported that prior financial statements should not be relied upon.","evidence_excerpt":"the need to restate certain previously issued financial statements as further described in Item 4.02 below","evidence_source":"SEC 8-K Item 4.01/4.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1503274/000150327424000014/0001503274-24-000014-index.htm","confidence":0.9,"family_label":"Auditor Changes","details":[{"label":"Action","value":"non reliance"}],"fact_type":"auditor_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}